ADMA Biologics Inc

ADMA Biologics develops, manufactures, and markets specialty plasma-derived biologics for immune deficiencies and infectious diseases. The company offers IVIG products BIVIGAM and ASCENIV, as well as Nabi-HB for Hepatitis B exposure. It also develops a pipeline of plasma-derived therapeutics and operates source plasma collection facilities. Products are sold through independent distributors, wholesalers, pharmacies, and alternate site providers.

Overview

Sector

Biotechnology

Target Price

22.4 USD

Current Price

15.4 USD

Potential

-62%

Strengths

Current Price to Earnings Ratio (18.63) is lower than the sector mean (91.15).
The company has high returns. ROIC (27.53%) is higher than the sector mean (6.02%).
Strong EBITDA Margin of 34.92%.

Weaknesses

With a depreciation Potential of -72.25%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.

Indicator	Value
PER	15.6
EV/EBITDA	8.1
Price/Free Cash Flow'	22.9
ROIC	8.6%
Net Debt/EBITDA	2.1

ADMA Biologics Inc

Overview

Strengths

Weaknesses

Key Financial Data